In the gastrointestinal tract, intraepithelial lymphocytes are tasked with protecting the epithelium against pathogens and participating in wound repair and correct mucosal barrier functioning. In a study published in the Sept. 15, 2023, issue of Science, researchers at King’s College London and collaborators have identified a specific subset of gamma-delta (γδ) T cells in the human gut, Vγ4 cells, which seems to protect against inflammatory bowel disease (IBD) progression.
A new drug that inhibits the glutamate carboxypeptidase II (GCPII) enzyme could be used to treat inflammatory bowel disease (IBD), according to a new study in mice and human organoids. After decades of research trying to design GCPII inhibitors against neurological disorders, the new compound could be effective for another use.
Researchers from China Pharmaceutical University have disclosed the discovery and preclinical evaluation of a new receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor, Zharp2-1, as a potential therapeutic candidate for the treatment of inflammatory bowel disease (IBD).
Microba Life Sciences Ltd. has started dosing patients in a phase I trial of its gut microbiome-derived therapeutic, MAP-315, for ulcerative colitis, the major form of inflammatory bowel disease (IBD).
Microba Life Sciences Ltd. has started dosing patients in a phase I trial of its gut microbiome-derived therapeutic, MAP-315, for ulcerative colitis, the major form of inflammatory bowel disease (IBD).
Just over a month after expressing “substantial doubt that the company can continue as a going concern,” Aeglea Biotherapeutics Inc. came back from the brink with a deal to take over Spyre Therapeutics Inc. in a stock-for-stock transaction, signed concurrently with an agreement to raise $210 million via the sale of series A preferred shares.
Regulatory T-cell specialist Quell Therapeutics Ltd. has sealed a potential $2 billion agreement under which Astrazeneca plc is taking rights to two autologous Treg cell therapies for treating inflammatory bowel disease (IBD) and type 1 diabetes. Quell will receive $85 million up front, the majority of which is in cash, with a modest (undisclosed) equity investment. Reaching the $2 billion headline figure will involve a series of development and commercial milestones and royalties on sales.
Liminal Biosciences Inc. has nominated a lead preclinical candidate, LMNL-6326, from its oxoeicosanoid receptor 1 (OXER1) antagonist program, targeting the treatment of eosinophil-driven diseases such as eosinophilic asthma and atopic dermatitis.
